Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

Nicholas J. Ashton,Wagner S. Brum,Guglielmo Di Molfetta,Andrea L. Benedet,Burak Arslan,Erin Jonaitis,Rebecca E. Langhough,Karly Cody,Rachael Wilson,Cynthia M. Carlsson,Eugeen Vanmechelen,Laia Montoliu-Gaya,Juan Lantero-Rodriguez,Nesrine Rahmouni,Cecile Tissot,Jenna Stevenson,Stijn Servaes,Joseph Therriault,Tharick Pascoal,Alberto Lleó,Daniel Alcolea,Juan Fortea,Pedro Rosa-Neto,Sterling Johnson,Andreas Jeromin,Kaj Blennow,Henrik Zetterberg

DOI: https://doi.org/10.1001/jamaneurol.2023.5319

IF: 29.907

2024-03-12

JAMA Neurology

Abstract:This cohort study examines data from 3 single-center observational cohorts to test the capabilities of a commercially available plasma phosphorylated tau 217 immunoassay to identify Alzheimer disease pathophysiology.

clinical neurology

What problem does this paper attempt to address?

The paper aims to address several key issues in the pathological diagnosis of Alzheimer's Disease (AD):

1. **Assessing the accuracy of a novel commercialized plasma phosphorylated Tau 217 (p-tau217) immunoassay**: The study aims to determine the effectiveness of this novel and commercializable immunoassay in detecting AD pathology (including abnormal amyloid-beta [Aβ] and Tau pathology) and compare it with traditional cerebrospinal fluid (CSF) biomarkers.

2. **Establishing reference ranges**: To establish reference ranges for plasma p-tau217 concentrations under abnormal Aβ and Tau pathological conditions, to better facilitate clinical diagnosis.

3. **Longitudinal change analysis**: To study the changes in plasma p-tau217 levels over time, particularly the trends under different pathological conditions (such as Aβ positive or Tau positive).

Through these studies, the authors hope to demonstrate that this novel plasma p-tau217 immunoassay can serve as a highly accurate and easy-to-use tool for early diagnosis of AD and monitoring disease progression. This will help improve patient management and timely access to disease-modifying treatments.